Scholarlink

<p>Clear cell renal cell carcinoma (ccRCC) represents a major subtype of kidney cancer with variable prognosis. A comprehensive understanding of sex hormone-related pathways could potentially refine the prediction of patient outcomes in ccRCC. Patients from TCGA-KIRC (<i>n</i> = 528) and GSE22541 (<i>n</i> = 40) cohorts were analyzed. Sex-hormone-associated pathways were manually collected and calculated with the activated score, then subtypes were identified. Differential gene expression, pathway enrichment, and tumor-infiltrating immunocytes were assessed. A prognostic signature was developed using Cox analysis and LASSO regression. Immunohistochemistry (IHC) was performed to validate the protein level of key model gene in ccRCC tissues. Three distinct subtypes (C1, C2, C3) based on sex hormone pathway activation were discovered. C1 showed the most favorable prognosis (<i>P</i> = 0.00029). 1,094 genes were upregulated in C1 and 197 in C3. 20 risk-associated and 172 protective genes for ccRCC prognosis were identified. LASSO regression narrowed down to 33 genes for the sex-hormone-related-gene (SHAG) prognostic model. In the TCGA-KIRC cohort, the high-SHAG score group had a worse prognosis with an HR of 3.26 (95% CI: 2.334–4.555, <i>P</i> &lt; 0.001). Validation in the GSE22541 cohort corroborated these findings. The nomogram incorporating the SHAG model demonstrated robust predictive accuracy higher than 0.75. IHC validation confirmed that ARHGEF17 protein levels were higher in early-stage ccRCC (stage I-II) compared to advanced-stage (stage III) tumors, supporting its prognostic relevance. The SHAG signature serves as a promising prognostic tool for ccRCC, providing insights into the role of sex hormone-related pathways in tumor progression. Further experimental and clinical validation is warranted to explore its potential in personalized therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Regulatory mechanism and prognostic value of sex hormone pathways connected with metabolism and immune signaling in clear cell renal cell carcinoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月18日

查看全文
  • Xinyu Geng,
  • Jiahao Shan,
  • Yu Dai,
  • Ziwei Liu,
  • Simin Min,
  • Shuo Zhao,
  • Zhengyuan Zhang,
  • Kai Shi,
  • Duobing Zhang,
  • Tuo Ji,
  • Baoyuan Chang

摘要

Clear cell renal cell carcinoma (ccRCC) represents a major subtype of kidney cancer with variable prognosis. A comprehensive understanding of sex hormone-related pathways could potentially refine the prediction of patient outcomes in ccRCC. Patients from TCGA-KIRC (n = 528) and GSE22541 (n = 40) cohorts were analyzed. Sex-hormone-associated pathways were manually collected and calculated with the activated score, then subtypes were identified. Differential gene expression, pathway enrichment, and tumor-infiltrating immunocytes were assessed. A prognostic signature was developed using Cox analysis and LASSO regression. Immunohistochemistry (IHC) was performed to validate the protein level of key model gene in ccRCC tissues. Three distinct subtypes (C1, C2, C3) based on sex hormone pathway activation were discovered. C1 showed the most favorable prognosis (P = 0.00029). 1,094 genes were upregulated in C1 and 197 in C3. 20 risk-associated and 172 protective genes for ccRCC prognosis were identified. LASSO regression narrowed down to 33 genes for the sex-hormone-related-gene (SHAG) prognostic model. In the TCGA-KIRC cohort, the high-SHAG score group had a worse prognosis with an HR of 3.26 (95% CI: 2.334–4.555, P < 0.001). Validation in the GSE22541 cohort corroborated these findings. The nomogram incorporating the SHAG model demonstrated robust predictive accuracy higher than 0.75. IHC validation confirmed that ARHGEF17 protein levels were higher in early-stage ccRCC (stage I-II) compared to advanced-stage (stage III) tumors, supporting its prognostic relevance. The SHAG signature serves as a promising prognostic tool for ccRCC, providing insights into the role of sex hormone-related pathways in tumor progression. Further experimental and clinical validation is warranted to explore its potential in personalized therapy.